Mon, Mar 2, 2015, 1:07 AM EST - U.S. Markets open in 8 hrs 23 mins


% | $
Quotes you view appear here for quick access.

Avanir Pharmaceuticals, Inc. Message Board

  • rayonman1 rayonman1 Jan 29, 2013 10:25 PM Flag

    Lyrica's quarterly sales were $1.132 billion

    Lyrica sales +13.4% yoy to $1.132 bln
    I think that's almost all for pain.
    So I'm guessing that is at least $4.2 billion at an annual rate for pain, even with competition from generic neurontin which is basically the same thing and probably cheaper.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • "Cymbalta sales +20.3% yoy to $1420 mln"
      These are quarterly sales, not yearly sales. Some of that $5.68 billion per year is for depression.
      Cymbalta is losing patent protection in the fourth quarter of this year (2013) so generic "Cymbalta" (venlafaxine?) will be cheaper than Cymbalta.
      Maybe it isn't such a good idea to be raising dex/quinidine's prices?

      • 2 Replies to rayonman1
      • "Maybe it isn't such a good idea to be raising dex/quinidine's prices?"

        N was never going to compete on price with Lyrica or Cymbalta and certainly not generics. In addition, over large populations it is also not likely to show dramatically better efficacy as a stand alone pain treatment than most of the above. However, the key is that it has a different mechanism of action that all the others. Thus, it may work in some patients where the others fail. Also, in patients whose pain is not completely relieved (which would be almost all chronic pain patients) the different mechanism of action makes it likely that it may be useful as add on therapy.

        It's not so terrible that N is likely to be 2nd or 3rd line. If N is proven effective for pain and captures just 1% of Lyrica and Cymbalta patients that would translate to annual sales of more than $300M.

      • vacationcharlie Jan 29, 2013 11:02 PM Flag

        Maybe you should cover and phack off Ray?

16.960.00(0.00%)Jan 12 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.